Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Lonafarnib in Progeria
NCT02579044Phase 2Enrolling by invitation
- Sponsor
- Boston Children's Hospital
- Start
- Dec 2015
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in Hutchinson-Gilford progeria syndrome (HGPS), sponsored by Boston Children's Hospital. Started Dec 2015; status: enrolling by invitation.
02
Drugs
everolimus
03
Conditions
Hutchinson-Gilford progeria syndrome (HGPS)
Beyond the preview
Go deeper on NCT02579044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579044.